Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis drug may be safe for patients with fatty liver

NCT ID NCT07683065

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 22, 2026 · Updated 5 times

Summary

This study looks at how long adults with plaque psoriasis and a common liver condition called MASLD (fatty liver disease) continue taking the drug secukinumab. Researchers will review medical records from several Spanish hospitals to track treatment duration and changes in liver health. The goal is to understand if secukinumab is a good long-term option for this group of patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
secukinumab
What this could lead to
If successful, this could show that secukinumab is a safe and effective long-term option for people with psoriasis who also have fatty liver disease.
What could go wrong
This is a retrospective study, not a controlled trial, so it can't prove cause and effect. Results may be influenced by how doctors chose treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE PLAQUE PSORIASIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Badalona, Barcelona, 08916, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28041, Spain

  • Novartis Investigative Site

    RECRUITING

    Málaga, 29010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.